All lobbying filings

BIOMARIN PHARMACEUTICAL INC.

Lobbying for BIOMARIN PHARMACEUTICAL INC.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $270,000.00 expenses · posted Oct 20, 2025

Official filing document

Bills named in this filing 5

HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025
HR 1509
Accelerating Kids’ Access to Care Act of 2025
S 752
Accelerating Kids’ Access to Care Act
S 1637
MVP Act

Lobbying activity 5

Budget/Appropriations

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG EXCLUSIVITY

Health Issues

H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM

Medicare/Medicaid

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS

Taxation/Internal Revenue Code

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.